Asston Pharmaceuticals IPO Lists Below Expectations Despite Demand, Trades Nearly 5% Lower on Debut

Mumbai, 16 July 2025: Shares of Asston Pharmaceuticals Ltd made a slow debut on the BSE SME platform today, opening at ₹119, a 3.25% discount to the IPO issue price of ₹123. As of 10:48 AM, the stock slipped further to ₹117.10, reflecting a 4.8% decline from its issue price, despite witnessing robust investor interest during the subscription period. However, as of 13:34 IST, the stock was trading at ₹124.90, slightly up ₹1.90 or 1.54%.

IPO Subscription Fails to Translate into Listing Gains

The company’s Initial Public Offering, which was open from July 9 to July 11, was subscribed 173.53 times. The IPO consisted of a fresh issue of 22.4 lakh equity shares, aggregating to ₹27.56 crore, with a price band of ₹115–₹123 per share.

However, the listing day performance did not mirror this demand, raising concerns among retail and institutional investors about short-term sentiment and valuation.

Weak Start in Early Trade Raises Market Concerns

Asston’s shares saw subdued movement in the morning session. Here’s a snapshot of early trading (as of 10:48 AM):

• Listing Price: ₹119.00
• Last Traded Price: ₹117.10
• Intraday High: ₹120.00
• Intraday Low: ₹113.05
• Previous Close (IPO Price): ₹123.00
• VWAP: ₹118.22
• Total Traded Quantity: 6.31 lakh shares
• Turnover: ₹7.46 crore
• Full Market Cap: ₹99.68 crore
• Free Float Market Cap: ₹18.81 crore

Despite initial volatility, the stock has not shown signs of recovery in the early session.

IPO Funds to be Used for Expansion and Working Capital

The company has outlined the following utilisation of IPO proceeds:

• Procurement of new machinery for its manufacturing unit
• Strengthening working capital
• Repayment or prepayment of certain borrowings
• General corporate expenses

These initiatives are aligned with the company’s aim to enhance operational capabilities and scale production.

Global Pharmaceutical Exporter with Certified Quality Standards

Asston Pharmaceuticals is engaged in the manufacture and export of pharmaceutical products including tablets, capsules, and syrups across a wide range of therapeutic categories. The company is FDA-certified and adheres to global Quality Management System (QMS) norms.

Its product portfolio addresses critical health segments such as pain relief, infections, and nutritional deficiencies, catering to domestic as well as international markets.

With the stock currently trading below its IPO price, market participants will be closely tracking its performance throughout the session. The key question remains whether the early dip is a short-term reaction or indicative of deeper valuation concerns.

REF: https://www.bseindia.com/stock-share-price/asston-pharmaceuticals-ltd/apl/544445/

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations